TBPH250117P10000
- 0.40
- 0.000.00%
Theravance Biopharma Newsroom
A Quick Look at Today's Ratings for Theravance Biopharma(TBPH.US), With a Forecast Between $9 to $15
Theravance Biopharma (TBPH) Receives a Hold From Evercore ISI
H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $15
Buy Rating Reaffirmed for Theravance Biopharma Amid Positive Momentum and Strategic Initiatives
Theravance Biopharma Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Theravance Biopharma Analyst Ratings
H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $15
Theravance Biopharma Price Target Cut to $15.00/Share From $20.00 by HC Wainwright & Co.
TD Cowen Maintains Hold on Theravance Biopharma, Lowers Price Target to $9
Theravance Biopharma Analyst Ratings
Theravance Biopharma (TBPH) Receives a Hold From Evercore ISI
Leerink Partners Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Cuts Target Price to $10
Evercore Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Maintains Target Price $11
Hold Rating on Theravance Biopharma Amidst Revised Revenue Projections and Pipeline Delays
H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Cuts Target Price to $15
Theravance Biopharma: Hold Rating Maintained Amid Adjusted Sales Expectations and Development Delays
HC Wainwright & Co. Reiterates Buy on Theravance Biopharma, Maintains $20 Price Target
Theravance Biopharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
Theravance Biopharma (TBPH) Receives a Hold From TD Cowen